NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines

Click here for details and downloads (registration is not required)URL: www.nec.com/en/global/solutions/ai-drug/publication/index.html

NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

In recent years, there have been growing expectations for personalized neoantigen cancer vaccines as a next-generation cancer therapy. Personalized neoantigen cancer vaccines are a type of cancer immunotherapy that targets neoantigens containing genomic mutations that are specific to each patient. NEC is working on the realization of personalized cancer vaccines by using one of its core technologies, AI, to identify target neoantigens from each individual patient's genome data.

This white paper proposes a comprehensive process workflow for personalized cancer vaccines, from design to administration, and the perspectives that should be discussed in this flow. Furthermore, NEC's advanced ICT technologies are introduced to address these perspectives, and the possibility that the use of ICT technology will contribute to the realization of a platform for not only personalized cancer vaccines, but also for various cancer treatments are discussed.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.

Source: NEC Corporation

Copyright 2024 JCN Newswire . All rights reserved.